- Home
- GROV vs INKT Comparison
GROV vs INKT Comparison
Compare GROV & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GROV
- INKT
- Stock Information
- Founded
- GROV 2016
- INKT 2017
- Country
- GROV United States
- INKT United States
- Employees
- GROV N/A
- INKT N/A
- Industry
- GROV Package Goods/Cosmetics
- INKT Medicinal Chemicals and Botanical Products
- Sector
- GROV Consumer Discretionary
- INKT Health Care
- Exchange
- GROV Nasdaq
- INKT Nasdaq
- Market Cap
- GROV 53.5M
- INKT 48.7M
- IPO Year
- GROV N/A
- INKT 2021
- Fundamental
- Price
- GROV $1.47
- INKT $14.90
- Analyst Decision
- GROV Buy
- INKT Buy
- Analyst Count
- GROV 2
- INKT 3
- Target Price
- GROV $1.35
- INKT $37.50
- AVG Volume (30 Days)
- GROV 101.6K
- INKT 157.5K
- Earning Date
- GROV 08-07-2025
- INKT 08-14-2025
- Dividend Yield
- GROV N/A
- INKT N/A
- EPS Growth
- GROV N/A
- INKT N/A
- EPS
- GROV N/A
- INKT N/A
- Revenue
- GROV $185,354,000.00
- INKT N/A
- Revenue This Year
- GROV N/A
- INKT N/A
- Revenue Next Year
- GROV $11.10
- INKT N/A
- P/E Ratio
- GROV N/A
- INKT N/A
- Revenue Growth
- GROV N/A
- INKT N/A
- 52 Week Low
- GROV $1.02
- INKT $4.56
- 52 Week High
- GROV $1.95
- INKT $76.00
- Technical
- Relative Strength Index (RSI)
- GROV 54.99
- INKT 49.19
- Support Level
- GROV $1.41
- INKT $14.25
- Resistance Level
- GROV $1.60
- INKT $15.48
- Average True Range (ATR)
- GROV 0.10
- INKT 1.77
- MACD
- GROV 0.00
- INKT -0.04
- Stochastic Oscillator
- GROV 60.23
- INKT 50.24
About GROV Grove Collaborative Holdings Inc.
Grove Collaborative Holdings Inc is engaged in providing consumer products. It offers Cleaning accessories, Home and Pantry, Personal care products, Pets supplements and Other products. It is a sustainability oriented consumer products generator. It use connection with consumers to create and curate authentic, disruptive brands and products. Company builds natural products that perform as well as, many consumer packaged goods (CPG) brands (both conventional and natural), while being healthier for consumers and the planet.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.